TAK-831
TAK-831-1501
Phase 2 small_molecule completed
Quick answer
TAK-831 for Friedreich Ataxia is a Phase 2 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Friedreich Ataxia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed